title: Peri-operative management of ophthalmic patients taking antithrombotic therapy.
abstract: Increasing number of patients presenting for ophthalmic surgery are using oral anti-coagulant and anti-platelet therapy. The current practice of discontinuing these drugs preoperatively because of a presumed increased risk of bleeding may not be evidence-based and could pose a significant risk to the patient's health. To provide an evidence-based review on the peri-operative management of ophthalmic patients who are taking anti-thrombotic therapy. In addition, we briefly discuss the underlying conditions that necessitate the use of these drugs as well as management of the operative field in anti-coagulated patients. A semi-systematic review of literature was performed. The databases searched included MEDLINE, EMBASE, database of abstracts of reviews of effects (DARE), Cochrane controlled trial register and Cochrane systematic reviews. In addition, the bibliographies of the included papers were also scanned for evidence. The published data suggests that aspirin did not appear to increase the risk of serious postoperative bleeding in any type of ophthalmic surgery. Topical, sub-tenon, peri-bulbar and retrobulbar anaesthesia appear to be safe in patients on anti-thrombotic (warfarin and aspirin) therapy. Warfarin does not increase the risk of significant bleeding in most types of ophthalmic surgery when the INR was within the therapeutic range. Current evidence supports the continued use of aspirin and with some exceptions, warfarin in the peri-operative period. The risk of thrombosis-related complications on disruption of anticoagulation may be higher than the risk of significant bleeding by continuing its use for most types of ophthalmic surgery.
authors.affiliation: Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK. g.y.h.lip@bham.ac.uk
authors.forename: G Y H
authors.initials: GY
authors.lastname: Lip
authors.forename: O M
authors.initials: OM
authors.lastname: Durrani
authors.forename: V
authors.initials: V
authors.lastname: Roldan
authors.forename: P L
authors.initials: PL
authors.lastname: Lip
authors.forename: F
authors.initials: F
authors.lastname: Marin
authors.forename: T Q
authors.initials: TQ
authors.lastname: Reuser
mesh_terms: D016063:Blood Loss, Surgical; D005128:Eye Diseases / Q000601:surgery*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006488:Hemostasis, Surgical; D006801:Humans; D007430:Intraoperative Care / Q000379:methods*; D013508:Ophthalmologic Surgical Procedures / Q000379:methods; D012307:Risk Factors; D013927:Thrombosis / Q000209:etiology
chemical_list: D005343:Fibrinolytic Agents